These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 12398021

  • 1. Lipid abnormalities in chronic renal failure, nephrotic syndrome and dialysis.
    Kes P.
    Acta Med Croatica; 2001; 55(4-5):177-86. PubMed ID: 12398021
    [Abstract] [Full Text] [Related]

  • 2. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
    Kes P, Reiner Z, Brunetta B.
    Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979
    [Abstract] [Full Text] [Related]

  • 3. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?
    Keane WF, St Peter JV, Kasiske BL.
    Kidney Int Suppl; 1992 Oct; 38():S134-41. PubMed ID: 1405364
    [Abstract] [Full Text] [Related]

  • 4. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H.
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
    [Abstract] [Full Text] [Related]

  • 5. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC, Saseen JJ.
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [Abstract] [Full Text] [Related]

  • 6. Effect of lipid-lowering dietary recommendations on the nutritional intake and lipid profiles of chronic peritoneal dialysis and hemodialysis patients.
    Saltissi D, Morgan C, Knight B, Chang W, Rigby R, Westhuyzen J.
    Am J Kidney Dis; 2001 Jun; 37(6):1209-15. PubMed ID: 11382690
    [Abstract] [Full Text] [Related]

  • 7. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI, Schreier L, Elbert A, Berg G, Beresan H, López G, Wikinski R.
    Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
    [Abstract] [Full Text] [Related]

  • 8. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.
    Tsimihodimos V, Dounousi E, Siamopoulos KC.
    Am J Nephrol; 2008 Jan; 28(6):958-73. PubMed ID: 18612199
    [Abstract] [Full Text] [Related]

  • 9. Lipid abnormalities associated with end-stage renal disease.
    Liu J, Rosner MH.
    Semin Dial; 2006 Jan; 19(1):32-40. PubMed ID: 16423180
    [Abstract] [Full Text] [Related]

  • 10. Optimizing end-stage renal disease therapy for the patient with diabetes mellitus.
    Friedlander MA, Hricik DE.
    Semin Nephrol; 1997 Jul; 17(4):331-45. PubMed ID: 9241718
    [Abstract] [Full Text] [Related]

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 12. Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines.
    Shoji T, Nishizawa Y.
    Ther Apher Dial; 2006 Aug; 10(4):305-15. PubMed ID: 16911182
    [Abstract] [Full Text] [Related]

  • 13. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait.
    Al-Rashidi M, Hussain AA, Nampoory MR, Al-Ali JH, Akanji AO.
    Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883
    [Abstract] [Full Text] [Related]

  • 14. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
    Wanner C, Krane V.
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S72-5. PubMed ID: 12612957
    [Abstract] [Full Text] [Related]

  • 15. Lipid and lipoprotein metabolism in chronic kidney disease.
    Kaysen GA.
    J Ren Nutr; 2009 Jan; 19(1):73-7. PubMed ID: 19121776
    [Abstract] [Full Text] [Related]

  • 16. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J, Santos F, Grosso D, Lima R, Barreira AL, Leite M, Mafra D, Abdalla DS.
    Nephron Clin Pract; 2008 Jan; 108(4):c298-304. PubMed ID: 18434752
    [Abstract] [Full Text] [Related]

  • 17. Disorders of protein and lipid metabolism associated with chronic renal failure and chronic dialysis.
    Krumlovsky FA.
    Ann Clin Lab Sci; 1981 Jan; 11(4):350-60. PubMed ID: 7023349
    [Abstract] [Full Text] [Related]

  • 18. Chlamydia pneumoniae infection and ischemic heart disease in hemodialysis patients.
    Wszola M, Kwiatkowski A, Nosek R, Podsiadly E, Meszaros J, Danielewicz R, Lisik W, Ostrowski K, Chmura A, Adadyński L, Paczek L, Durlik M, Tylewska-Wierzbanowska S, Rowiński W.
    Transplant Proc; 2006 Jan; 38(1):31-4. PubMed ID: 16504656
    [Abstract] [Full Text] [Related]

  • 19. The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients.
    Sit D, Kadiroglu AK, Yilmaz ME, Kara IH, Isikoglu B.
    Ren Fail; 2005 Jan; 27(4):403-7. PubMed ID: 16060127
    [Abstract] [Full Text] [Related]

  • 20. Treatment of dyslipidemia in chronic kidney disease.
    Stefanovic V, Milojkovic M.
    Int J Artif Organs; 2004 Oct; 27(10):821-7. PubMed ID: 15560675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.